37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcinoma

37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcinoma

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Vol. 29; no. Supplement_1; pp. S23 - S24
Main Authors: Ebrahimi, Hedyeh, Berardi, Andrea, Smare, Caitlin, Pavlidou, Eleni, Guttenplan, Sarah B, Eiffert, Sam, Rosenblatt, Lisa, Kurt, Murat, Yin, Xin, Chehrazi-Raffle, Alexander
Format: Journal Article
Language:English
Published: US Oxford University Press 06-08-2024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:1083-7159
1549-490X
DOI:10.1093/oncolo/oyae181.038